Famotidine Dosing Recommendations
For adults with normal renal function, famotidine dosing ranges from 20 mg twice daily for GERD to 40 mg once daily (or 20 mg twice daily) for active ulcers, with mandatory dose reductions required when creatinine clearance falls below 60 mL/min. 1
Adult Dosing (Normal Renal Function)
The FDA-approved dosing varies by indication 1:
- Active duodenal ulcer: 40 mg once daily OR 20 mg twice daily for up to 8 weeks
- Active gastric ulcer: 40 mg once daily for up to 8 weeks
- Symptomatic non-erosive GERD: 20 mg twice daily for up to 6 weeks
- Erosive esophagitis: 20 mg twice daily OR 40 mg twice daily for up to 12 weeks
- Ulcer recurrence prevention: 20 mg once daily for 1 year
- Pathological hypersecretory conditions: Starting dose 20 mg every 6 hours, titrate to patient needs (maximum 160 mg every 6 hours)
Critical Care Context
For stress ulcer prophylaxis in ICU patients, use low-dose famotidine defined as ≤40 mg daily 2. Higher doses provide no additional benefit and may increase adverse effects. H2-receptor antagonists like famotidine are associated with less mortality risk compared to PPIs in critically ill patients, though they have slightly higher bleeding rates 2.
Pediatric Dosing
For children weighing ≥40 kg, use adult dosing regimens 1. The 20 mg and 40 mg tablet formulations should not be used in children <40 kg as the lowest strength exceeds recommended doses for this population.
**For children <40 kg (requiring liquid formulation): 1 mg/kg/day divided into 2 doses** 3. This applies to children aged 1-16 years with GERD. Research supports that children >3 months of age have pharmacokinetics similar to adults, allowing dosing of 0.5 mg/kg every 8-12 hours 4, 5.
For infants <3 months: Use reduced frequency (once daily rather than twice daily) due to immature renal function that decreases famotidine clearance 4. Plasma and renal clearance are significantly reduced in this age group compared to older infants.
Renal Impairment Dosing (Critical)
Dose adjustments are mandatory when creatinine clearance <60 mL/min 1:
Moderate Impairment (CrCl 30-60 mL/min):
- All indications: Maximum 20 mg once daily OR 40 mg every other day
- Half-life increases to approximately 4.7 hours (vs 2.6 hours in normal function) 6
Severe Impairment (CrCl <30 mL/min):
- All indications: Maximum 20 mg every other day (or 10 mg once daily using alternate formulation)
- Half-life increases dramatically to 12 hours 6
- Pathological hypersecretory conditions: Avoid use entirely 1
Dialysis Patients:
- 20 mg orally immediately after each dialysis session (60 mg/week total) is optimal 7
- Dialysis removes approximately 42% of famotidine 7
- Half-life extends to 22.5 hours in dialysis patients 7
Key Clinical Pitfalls
Tachyphylaxis develops within 6 weeks, limiting long-term H2RA effectiveness 3. This rapid tolerance is a major limitation compared to PPIs for chronic therapy.
Do not use standard doses in renal impairment—approximately 70% of famotidine is renally excreted, primarily via tubular secretion 6. Failure to adjust doses risks drug accumulation and adverse effects.
Timing: Administer once-daily doses before bedtime; twice-daily doses in morning and before bedtime 1. May be taken with or without food and can be co-administered with antacids 1.
Pediatric monitoring: Intravenous famotidine shows decreased efficacy duration with repeated dosing in children, necessitating pH monitoring for prolonged IV use 8.